Therefore, the availability of this new drug offers the possibility to test the potential beneficial effect of activation of β3-AR to prevent and/or delay myocardial remodeling in patients at high risk of developing HF as add-on therapy. This evidence concerns the gene ADRB3 and hydrops fetalis.